These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update. Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932 [TBL] [Abstract][Full Text] [Related]
5. Research advance in lipid nanoparticle-mRNA delivery system and its application in CAR-T cell therapy. Ye B; Hu Y; Zhang M; Huang H Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):185-191. PubMed ID: 36161298 [TBL] [Abstract][Full Text] [Related]
6. In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism. Billingsley MM; Gong N; Mukalel AJ; Thatte AS; El-Mayta R; Patel SK; Metzloff AE; Swingle KL; Han X; Xue L; Hamilton AG; Safford HC; Alameh MG; Papp TE; Parhiz H; Weissman D; Mitchell MJ Small; 2024 Mar; 20(11):e2304378. PubMed ID: 38072809 [TBL] [Abstract][Full Text] [Related]
7. Orthogonal Design of Experiments for Optimization of Lipid Nanoparticles for mRNA Engineering of CAR T Cells. Billingsley MM; Hamilton AG; Mai D; Patel SK; Swingle KL; Sheppard NC; June CH; Mitchell MJ Nano Lett; 2022 Jan; 22(1):533-542. PubMed ID: 34669421 [TBL] [Abstract][Full Text] [Related]
8. Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases: Advances in genome editing and CAR T cell therapy. Soroudi S; Jaafari MR; Arabi L J Control Release; 2024 Aug; 372():113-140. PubMed ID: 38876358 [TBL] [Abstract][Full Text] [Related]
9. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors. Sloas C; Gill S; Klichinsky M Front Immunol; 2021; 12():783305. PubMed ID: 34899748 [TBL] [Abstract][Full Text] [Related]
10. Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy. Metzloff AE; Padilla MS; Gong N; Billingsley MM; Han X; Merolle M; Mai D; Figueroa-Espada CG; Thatte AS; Haley RM; Mukalel AJ; Hamilton AG; Alameh MG; Weissman D; Sheppard NC; June CH; Mitchell MJ Adv Mater; 2024 Jun; 36(26):e2313226. PubMed ID: 38419362 [TBL] [Abstract][Full Text] [Related]
11. CAR T cells produced in vivo to treat cardiac injury. Rurik JG; Tombácz I; Yadegari A; Méndez Fernández PO; Shewale SV; Li L; Kimura T; Soliman OY; Papp TE; Tam YK; Mui BL; Albelda SM; Puré E; June CH; Aghajanian H; Weissman D; Parhiz H; Epstein JA Science; 2022 Jan; 375(6576):91-96. PubMed ID: 34990237 [TBL] [Abstract][Full Text] [Related]
13. CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo. Golubovskaya V; Sienkiewicz J; Sun J; Zhang S; Huang Y; Zhou H; Harto H; Xu S; Berahovich R; Wu L Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686170 [TBL] [Abstract][Full Text] [Related]
14. Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering. Kitte R; Rabel M; Geczy R; Park S; Fricke S; Koehl U; Tretbar US Mol Ther Methods Clin Dev; 2023 Dec; 31():101139. PubMed ID: 38027056 [TBL] [Abstract][Full Text] [Related]
15. Lipid Nanoparticle-mRNA Formulations for Therapeutic Applications. Wang C; Zhang Y; Dong Y Acc Chem Res; 2021 Dec; 54(23):4283-4293. PubMed ID: 34793124 [TBL] [Abstract][Full Text] [Related]
16. Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy. Shin S; Lee P; Han J; Kim SN; Lim J; Park DH; Paik T; Min J; Park CG; Park W Tissue Eng Regen Med; 2023 Jun; 20(3):371-387. PubMed ID: 36867402 [TBL] [Abstract][Full Text] [Related]
17. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2 Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641 [No Abstract] [Full Text] [Related]